

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-5. (Canceled)

6. (Currently Amended) An isolated polynucleotide comprising at least the open reading frame of the sequence recited in SEQ ID NO:474, or the complement thereof.

7-80. (Canceled)

81. (Currently Amended) An expression vector comprising the polynucleotide of any one of claims 6 ~~and, claims 85-89~~ 86, and 88-89 operably linked to an expression control element.

82. (Currently Amended) A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component comprising the polynucleotide according to any one of claims 6 ~~and claims 85-89~~ 86, and 88-89.

83. (Canceled)

84. (Currently Amended) A diagnostic kit comprising at least one ~~oligonucleotide~~ polynucleotide according to claim ~~83~~ 86.

85. (Canceled)

86. (Currently Amended) An isolated polynucleotide useful in the detection of breast cancer comprising a sequence consisting of at least 20 contiguous nucleotides of the sequence provided in SEQ ID NO:474, or the complement thereof.

87. (Canceled)

88. (Previously Presented) An isolated polynucleotide useful in the detection of breast cancer comprising a sequence having at least 90% identity to the sequence of SEQ ID NO:474.

89. (Previously Presented) An isolated polynucleotide useful in the detection of breast cancer comprising a degenerate variant of the sequence provided in SEQ ID NO:474.